Incyte Q4 revenue up 16% to $1.2 billion; 2024 GAAP profit falls sharply
Incyte reported fourth-quarter 2024 total revenues of $1.2 billion, up 16% year over year, and full-year revenues of $4.2 billion, up 15%. Full-year GAAP net income fell to $32.6 million from $597.6 million, mainly because of a $679.4 million charge for in-process R&D assets acquired with Escient and a $100.0 million milestone payment to MacroGenics. The company also gave 2025 guidance for Jakafi and Opzelura net product revenues.
Key points
- Q4 2024 GAAP net income was $201.2 million, or $1.02 per diluted share, versus $201.1 million, or $0.89, a year earlier
- Full-year 2024 GAAP diluted EPS was $0.15, compared with $2.65 in 2023
- 2025 guidance: Jakafi net product revenues of $2,925 million to $2,975 million; Opzelura $630 million to $670 million
- Cash, cash equivalents and marketable securities were $2.2 billion at December 31, 2024, down from $3.7 billion, mainly due to a $2.0 billion share repurchase in June 2024
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.